NIKKEI 225
38,090.87 +129.07 (+0.34%) HANG SENG
16,434.83 +182.99 (+1.13%) CRUDE OIL
82.82 +0.13 (+0.16%) GOLD FUTURES
2,388.60 +0.20 (+0.01%) DOW
37,753.31 -45.66 (-0.12%) Bitcoin GBP
49,681.57 -1,720.24 (-3.35%)
MRNA Apr 2024 130.000 call
| Previous close | 0.0200 |
| Open | 0.0100 |
| Bid | 0.0100 |
| Ask | 0.0300 |
| Strike | 130.00 |
| Expiry date | 2024-04-19 |
| Day's range | 0.0100 - 0.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.54k |
ZacksModerna (MRNA) Stock Moves -0.34%: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
FortuneHow Moderna’s CIO helps steer the drugmaker’s post-COVID evolution
Brad Miller is helping Moderna shift from its reliance on COVID vaccines, with the company hoping to introduce up to 15 new drugs over a five-year period.
BenzingaJohnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue
